In the closing of the recent trading day, Novavax (NVAX) stood at $10, denoting a -1.19% change from the preceding trading day.

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.14 which represents a decrease of $-0.04 or -0.39% from the prior close of $10.18. The stock opened at $10.1 and touched a low ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

In the latest market close, Novavax (NVAX) reached $10.35, with a +1.97% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 0.02%. On the other ...

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.